Q3 Net Loss Widens to $56.9M as PIVOT-006 Topline Data Nears This Month
CGON sits 81% above its 52-week low of $35.8.
Summary
CG Oncology posted a Q3 2026 net loss of $56.9 million, or $0.64 per share, wider than the $43.8 million loss a year ago, driven by R&D expenses climbing to $39.2 million from $27.9 million on higher clinical trial and CMC costs. Cash and marketable securities stood at $984.5 million as of September 30, down modestly from $1.0 billion at June 30, with the company guiding that this funds operations through 2029. The real driver for the stock is the pipeline calendar: PIVOT-006 Phase 3 topline data in intermediate-risk and high-grade Ta NMIBC is due this month, with 12-month data from CORE-008 Cohort CX and BOND-003 Cohort P in December and completion of the BLA submission in BCG-unresponsive NMIBC with CIS targeted for Q4 2026. The company also named Isabel Kalofonos as Chief Commercial Officer in October, a hire pointing toward launch preparation. The financials are largely secondary here; the PIVOT-006 readout this month is the binary event that will set the stock's direction.
At the time of this announcement, CGON was trading at $64.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7B. The 52-week trading range was $35.80 to $80.97. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.